Netflix’s accelerating ad business, AI-driven innovation, content strength, focus on originals across various genres and languages are key positives.

Various sales-boosting initiatives and cost-saving efforts undertaken by the company are expected to drive growth.

Kroger drives growth with digital expansion, private label success, fresh offerings and strategic partnerships, while investments in AI and value creation fuel long-term scalability.

 We are impressed by the company's efforts to modernize its fleet.

Central Garden & Pet advances digital, supply chain and product innovation while driving margin gains and M&A, backed by strong financials and a focused Cost and Simplicity program.

Strength across all product groups is a positive catalyst for Edwards Lifesciences. The company’s bullish long-term growth strategy buoys optimism on the stock.

Amgen’s key medicines like Evenity and Repatha as well as newer medicines like Tavneos and Tezspire are driving sales, more than offsetting declining revenues from oncology biosimilars and legacy established products such as Enbrel

AbbVie’s Skyrizi and Rinvoq, are performing extremely well, bolstered by approval in new indications, which should support top-line growth in the next few years.

Robust vehicle offerings, a growing software and services business, progress in China restructuring, and investor-friendly moves are expected to support General Motors’ growth. 

Target’s accelerating digital ecosystem, marketplace expansion, shrink improvement, and high-margin non-merchandise streams, supported by advanced tech and AI, enhance profitability and omnichannel scale.